Binkow & Goldberg LLP announces that a class action lawsuit has
been filed in the United States District Court for the District of Utah
on behalf of a class (the "Class") comprising all purchasers of the
common stock of Nu
Skin Enterprises, Inc. ("Nu Skin" or the "Company") (NYSE:NUS)
between July 10, 2013 and January 14, 2014, inclusive (the "Class
A COPY OF THE COMPLAINT
IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE
CONTACT US TOLL-FREE AT (888) 773-9224, OR AT (212) 682-5340, OR BY
EMAIL TO SHAREHOLDERS@GLANCYLAW.COM
TO DISCUSS THIS MATTER. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR
MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
Nu Skin develops and distributes anti-aging personal care products and
nutritional supplements worldwide under the Nu Skin and Pharmanex
brands. The Complaint alleges that the Company and certain of its
executive officers made material misstatements or failed to disclose
material facts, throughout the Class Period, concerning Nu Skin's
business, operations and financial prospects. Specifically, defendants
misrepresented or failed to disclose that the Company's business
practices in China operated as an illegal pyramid scheme and did not
comply with local laws and regulations, and the Company's rapid growth
and revenue increase could not continue without its China business.
If you are a member of the Class described above, you may move the Court
no later than March 24, 2014, to serve as lead plaintiff; however, you
must meet certain legal requirements. To be a member of the Class, you
need not take any action at this time or you may retain counsel of your
choice. If you wish to learn more about this action or have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to email@example.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To NFVZone's Homepage ]